These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37601693)

  • 1. Targeting MCL-1 protein to treat cancer: opportunities and challenges.
    Tantawy SI; Timofeeva N; Sarkar A; Gandhi V
    Front Oncol; 2023; 13():1226289. PubMed ID: 37601693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
    Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
    Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
    J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.
    Diepstraten ST; Anderson MA; Czabotar PE; Lessene G; Strasser A; Kelly GL
    Nat Rev Cancer; 2022 Jan; 22(1):45-64. PubMed ID: 34663943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.
    Bolomsky A; Miettinen JJ; Malyutina A; Besse A; Huber J; Fellinger S; Breid H; Parsons A; Klavins K; Hannich JT; Kubicek S; Caers J; Hübl W; Schreder M; Zojer N; Driessen C; Tang J; Besse L; Heckman CA; Ludwig H
    Blood Adv; 2021 Oct; 5(20):4125-4139. PubMed ID: 34478517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.
    Tantawy SI; Sarkar A; Hubner S; Tan Z; Wierda WG; Eldeib A; Zhang S; Kornblau S; Gandhi V
    Clin Cancer Res; 2023 Jan; 29(2):446-457. PubMed ID: 36346691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it.
    Sulkshane P; Teni T
    Explor Target Antitumor Ther; 2022; 3(3):278-296. PubMed ID: 36045907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
    Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
    Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
    Carter BZ; Mak PY; Tao W; Zhang Q; Ruvolo V; Kuruvilla VM; Wang X; Mak DH; Battula VL; Konopleva M; Jabbour EJ; Hughes PE; Chen X; Morrow PK; Andreeff M
    Mol Cancer Ther; 2022 Jun; 21(6):879-889. PubMed ID: 35364607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
    Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
    Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.